EFFECT OF DICLOFENAС SODIUM ON MECHANISMS OF DIFFERENTIATION OF BONE MARROW CELLS AND PERIPHERAL BLOOD: A LITERATURE REVIEW

  • Yu. Bahmut Kharkiv Medical Academy of Postgraduate Education, Kharkiv
  • O. S. Ivanov Kharkiv Medical Academy of Postgraduate Education, Kharkiv
  • G. V. Tsapko Kharkiv Medical Academy of Postgraduate Education, Kharkiv
Keywords: bone marrow, Diclofenac Sodium, erythrocytes, myelocytes, toxic effect

Abstract

The hematopoietic system is a population of many cells that perform certain functions in the body. The pharmaceutical industry creates new drugs from the group of nonsteroidal anti-inflammatory drugs, but the “gold” standard remains the drug Diclofenac Sodium. In some conditions, a person is forced to take the drug for a long time, and sometimes all life. The mechanism of the drug effect on the bone marrow cells under the condition of long-term administration remains unclear. In the process of analyzing the literature, it has been established that the use of the drug has a toxic effect on the blood cells and blood-forming organs. Gradually, the toxic effect is reduced, but the long-term effect of the drug on the rat organism contributes to the inhibition of the development of erythrocyte and myelocytic sprouts of the bone marrow. A period of up to 10 days is optimal for use, and then it is worthwhile to look for a drug that is safer for the body.

Downloads

Download data is not yet available.

References

1. Danilova I. G. Vliyaniye sistemy fagotsitiruyushchikh mononuklearov na eritropoez v eritroblasticheskikh ostrovkakh kostnogo mozga / I. G. Danilova, B. G. Yushkov, M. V. Ulitko [i dr.] // Med. immunologiya. – 2006. - T. 8, N 2/3. - S. 135.
2. Leontyuk A. S. Osnovy vozrastnoy gistologii / A. S. Leontyuk, B. A. Sluka // Minsk :Vysheyshaya shkola, -2000, 418 s.
3. Deryvedmidʹ L.V. Kombinovani khondroprotektory pry likuvanni osteoartrytu / L.V. Deryvedmidʹ, V.P. Vereitynova // Bilʹ, suhloby, khrebet. – 2018. – Tom 8, №1. – S.31-36.
4. Hryshchenko V.A. Hematolohichnyy profilʹ u shchuriv pry eksperymentalʹnomu dyklofenak-indukovanomu hepatyti / A.V. Hryshchenko // UkrainianJournalofEcology. – 2017. – 7(3). – S.78–83.
5. Selyuk M.N. Novyye grani klassicheskogo nesteroidnogo protivovospalitel'nogo sredstva diklofenak / M.N. Selyuk, N.N. Kozachok, O.V. Selyuk // Suchasní preparati ta tekhnologíí̈. – 2013. – ML№8 (104). – S. 35-40.
6. Karateyev A.Ye. Ratsional'noye primeneniye nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoy praktike / A.Ye. Karateyev, Ye.L. Nasonov, N.N. Yakhno i dr. // Sovremennaya revmatologiya. – 2015. – №1.15. – S. 7-23.
7. Karateyev A.Ye. NPVP-Gastropatiya: Dinamika za 12 let / A.Ye. Karateyev // Nauchno-prakticheskaya revmatologiya. – 2011. – №3. – S. 20-24.
8. Karateyev A.Ye. Ratsional'noye ispol'zovaniye nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskiye rekomendatsii / A.Ye. Karateyev, Ye.L. Nasonov, V.T. Ivashkin i dr // Nauchno-prakticheskaya revmatologiya. – 2018. – №56(pril 1.). – S. 1-29.
9. Kozachok N.N. Nesteroidnyye protivovospalitel'nyye preparaty – kto lidiruyet v sovremennoy klinike? / N.N. Kozachok, M.M. Selyuk, S.A. Bychkova, N.G. Bychkova // Novosti meditsiny i farmatsii. – 2008. – №4(235).
10. Gladkikh F. V. Kharakteristika terapevtichnogo yefektu íbuprofenu ta yogo kombínatsíí̈ z vínboronom za danimi gematolog̀íchnikh pokaznikív na modelí ad'yuvantnogo artritu u shchurív / F. V. Gladkikh, N. G. Stepanyuk // ActamedicaLeopoliensia. – 2015. – T. 21, № 4. – S. 64-70.
11. OrinyaAgbajiOrinyaHaematologicalandbiochemicalstudiesontheeffectofdiclofenacSodiumonWistar Rattusnorvegicus / OrinyaAgbajiOrinya, AdeshinaYahayaAdenkola, RaphaelJohnOgbe // InternationalJournalofBiologicalandChemicalSciences. – 2016. – 10(5). – P. 2231-2242.
12. Chouhan S. Potential risks of aberration in bone histology and myelotoxity after continuous Diclofenac use in BALB/C mice model / S. Chouhan, S. Sharma // Proceedings of International Conference on Anthropogenic Impact on Environment & Conservation Strategy. – November 02 - 04, 2012, Ranchi.
13. Miyamoto, G., Zahid, N. and Uetrecht, J. P. 1997. Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem. Res. Toxicol. 10(4): 414–419.
14. Sosin, M. and Handa S. 2003. Low dose methotrexate and bone marrow suppression. BMJ. 326: 266-267.
15. Merchant, M. A. and Modi, D. N. 2004. Acute and chronic effects of aspirin on hematological parameters and hepatic ferritin expression in mice. Indian J. Pharmacol. 36(4): 226-230.
16. Lorenz, M., Slaughter, H. S., Wescott, D. M., Carter, S. I., Schnyder, B., Dinchuk, J. E. and Car, B. D. 1999. Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil–induced myelotoxicity in mice. Exp. Hematol. 27: 1494–1502.
17. Fisher, J. W., Radtke, H. W., Jubiz, W., Nelson, P. K., Burdowski, A. 1980. Prostaglandins activation of erythropoietin production and erythroid progenitor cells. Exp. Hematol. 8: 65-89.
Published
2018-12-26
How to Cite
Bahmut, Y., Ivanov, O. S., & Tsapko, G. V. (2018). EFFECT OF DICLOFENAС SODIUM ON MECHANISMS OF DIFFERENTIATION OF BONE MARROW CELLS AND PERIPHERAL BLOOD: A LITERATURE REVIEW. The Medical and Ecological Problems, 22(5-6), 22-24. https://doi.org/10.31718/mep.2018.22.5-6.05